Jobs
View more job listings or post a job
Variant Bio (Senior) Scientist - DMPK
Alturas Analytics Scientist 1
University of California, Davis TOXICOLOGY ANALYTICAL CHEMIST (STAFF RESEARCH ASSOCIATE 3)
University of California, Davis CALIFORNIA ANIMAL HEALTH AND FOOD SAFETY LABORATORY - TOXICOLOGY LAB RESEARCH SUPERVISOR/GROUP LEADER
Eli Lilly and Company R-39973 Scientific Director ADME - Novel Modalities (Open)
FibroGen Director DMPK
Applied BioMath Technical Marketing Specialist
Horizon Therapeutics Director, Bioanalytical Sciences
Exelixis Principal Scientist - DMPK
Exelixis Senior Principal Scientist - DMPK
Post a job

Workshop

Small-Molecule Bioanalytical Method Validation & Regulated Bioanalysis: Fundamentals, the New FDA Guidance and Regulatory Trends


Speakers: Mark Rose, CHDI; David Humphries, Covance; Kristen Harman, ChemoCentryx; David Scharberg, Pharmaceutical Outsource Solutions; Steve Lowes, Q2 Solutions; Eric Woolf, Merck; Deqing Xiao, Gilead
Organizers: Thomas Tarnowski, Gilead; Kristen Harman, ChemoCentryx
Date: 2019-10-03
Time: 8:45-17:00 Pacific Time
Registration fee: (USD): Regular: $195; Academic: $125; For unemployed or students: $30; For vendor-show rep: $35; For major-sponsor rep (incl lunch): $0
Location: SF Bay Area: Foster City Crowne Plaza
Major Sponsor: (3)Alturas Analytics; Eurofins Bioanalytical Services; WORLDWIDE CLINICAL TRIALS
Vendor show vendors registered to date: (17)AB Sciex; Absorption Systems; BASi/Seventh Wave; Celerion; ICON Clinical Research; Intertek; KCAS Bioanalytical & Biomarker Services; Kelly Science & Clinical; Laviana Pharma; Medpace; MicroConstants; Mycenax; Pacific BioLabs; Pharmaron; Quintara Discovery (QDI); SEKISUI XenoTech; syngene intl
Registration: http://www.PBSS.org
Registration deadline:2019-10-01  (it will close sooner if the seating cap is reached)

About the Topic

Regulated bioanalysis (RBA) is required in the key parts of drug development that involve evaluations of drug safety, bioequivalence, and pharmacokinetics, and RBA data quality directly impacts the reliability of such assessments. RBA Method Validation requires compliance with various national method validation guidances, which will soon be superseded by harmonized guidance from the International Conference on Harmonisation (ICH).

To ensure successful assay applications and regulatory submissions, bioanalytical methods are extensively evaluated and validated for accuracy/precision, selectivity, specificity, sensitivity, recovery, and stability under various operational conditions. Data generated for validation and sample analyses and all documentation necessary for reconstructing the validation study and sample analyses, (e.g. experimental data, protocols, reports, staff training records, SOPs, etc.) needs to be maintained and available for data audit and inspection.

Presenters at this workshop are internationally recognized experts on RBA and regularly present at international bioanalytical conferences. The workshop includes a general introduction to regulated bioanalytical method development/validation and sample analysis, as well as presentations of things to consider when partnering with a bioanalytical contract research organization (CRO) to perform such work. Presenters will also cover how to comply with the guidances and regulations, and discuss recent topics relating to the newest FDA Bioanalytical Method Validation guidance and the draft ICH guidance.


Workshop Agenda:

8:45 - 9:00   Welcome - S.Miao & T.Tarnowski

9:00 - 10:30    1. Introduction to Regulated Bioanalysis - Mark Rose, CHDI Management, Inc.

10:30 - 10:40    Major Sponsor Presentation - Alturas

10:40 - 11:00    Break

11:00 - 11:30    2. Quality and Compliance for Regulated Bioanalysis - David Scharberg, Preclinical Outsourcing Services

11:30 - 12:00    3. Working successfully with Bioanalytical CROs (CRO Experience) - David Humphries, Covance

12:00 - 12:20   4. Working successfully with Bioanalytical CROs (Sponsor Experience) - Kristen Harman, ChemoCentryx

12:20 - 1:20   Lunch (Sponsored by Eurofins Bioanalytical Services)

1:20 - 2:15    5. Interpretation and Application of the 2018 FDA Guidance on Bioanalytical Method Validation - Steve Lowes, Q2 Solutions

2:15 - 2:25    Major Sponsor Presentation - Worldwide Clinical Trials

2:25 - 2:45    Break & Raffle

2:45 - 3:40    6. ICH M10 The Road to a Global Harmonized Bioanalytical Method Validation Guidance - Eric Woolf, Merck

3:40 – 4:20   7. Strategies for Determination of Small-Molecule Analytes in PBMCs - Deqing Xiao, Gilead

4:20 - 4:50  Q&A for Speaker Panel - All


2024-03-07, [In-Person] Project/Program Management Elevating Drug Development
2024-03-15, [Free Online] Oncology Business Development and Partnering: perspectives and advice from buyers
2024-03-28, [In-Person] Antibody-Drug Conjugates from Discovery to Development: Chemistry, Engineering, Characterization, CMC, PK/Tox, Clinical design and Intellectual Property
2024-04-12, [Free Online] Innovative Life Science Technologies in the Drug Development Toolbox: From Cancer Organoids and Biomarker Profiling to Label-Free Multiplex QES Assays
2024-04-26, [In-Person] Oncology Clinical Dose Optimization in Light of FDA Project Optimus
2024-05-06, [In-Person] Human Mass Balance and Metabolite Profiling Studies: Strategies, Technical Approaches, Regulatory Guidance, Applications and Case Studies
2024-05-21, [In-Person] Nonclinical Safety Studies for IND and NDA Filing for Small Molecules: Nuts, Bolts and Best Practices
2024-06-13, [In-Person] CMC Strategies and Activities for IND and NDA Filing for Small Molecules: Nuts, Bolts and Best Practices
2024-09-10, [In-Person] Translational PK/PD considerations for Novel Modalities
2024-09-20, [In-Person] Non-clinical safety assessments of biologics and novel modalities for IND/NDA Filing: Nuts, Bolts and Best Practices
┬ęPharmaceutical & BioScience Society, International; Last Modified: 2/24/2024; Admin Logon
Ads (in random order)
Submit a Text Ad
($250 for 2 months)

Alturas Analytics, Inc. Expert GLP & non-GLP LC-MS/MS, GC-MS/MS bioanalytical & PK/TK analysis services of small & large molecules in any matrix. Discovery through phase IV.
Lena Biosciences Predictive toxicology. Mitochondrial toxicity in a drug metabolism-competent model with active transporters. Intrinsic & idiosyncratic DILI.
Submit a Text Ad